TABLE 2.
Questionnaires for the assessment of fatigue symptoms and cognitive impairment
|
Mx group (n = 32) |
UC group (n = 32) |
SMx group (n = 32) |
|||||
|---|---|---|---|---|---|---|---|
| Mean (95% CI) | Mean (95% CI) | Mean difference Mx‐UC (95% CI) | p † | Mean (95% CI) |
Mean difference Mx‐SMx (95% CI) |
p † | |
| BFI | |||||||
| Baseline | 6.19 (5.71, 6.67) | 6.30 (5.86, 6.74) | 6.06 (5.64, 6.49) | ||||
| Week 9 | 4.27 (3.77, 4.76) | 5.87 (5.32, 6.41) | −0.76 (−1.06, −0.47) | <0.001* | 4.34 (3.80, 4.90) | −0.13 (−0.83, 0.57) | 0.712 |
|
p ‡ |
<0.001* | 0.036* | <0.001* | ||||
| Week 13 | 3.83 (3.28, 4.37) | 6.00 (5.46, 6.53) | −1.06 (−1.41, −0.71) | <0.001* | 4.98 (4.40, 5.55) | −1.17 (−1.96, −0.39) | 0.004* |
| p ‡ | <0.001* | 0.186 | 0.001* | ||||
| FACT‐F | |||||||
| Baseline | 23.91 (21.30, 26.51) | 23.88 (21.09, 26.66) | 23.31 (21.09, 25.54) | ||||
| Week 9 | 33.25 (31.09, 35.41) | 25.25 (22.33, 28.17) | 3.99 (2.49, 5.50) | <0.001* | 31.65 (29.52, 33.78) | 1.47 (−1.51, 4.45) | 0.334 |
| p ‡ | <0.001* | 0.152 | <0.001* | ||||
| Week 13 | 32.42 (29.71, 35.13) | 25.34 (22.32, 28.37) | 3.53 (1.89, 5.16) | <0.001* | 29.72 (27.15, 32.29) | 2.43 (−0.97, 5.84) | 0.161 |
| p ‡ | <0.001* | 0.135 | <0.001* | ||||
| MoCA‐K | |||||||
| Baseline | 27.41 (26.65, 28.16) | 26.97 (26.23, 27.71) | 25.53 (24.39, 26.67) | ||||
| Week 9 | 28.41 (27.88, 28.95) | 28.16 (27.60, 28.71) | 0.04 (−0.28, 0.36) | 0.820 | 27.13 (26.12, 28.15) | 0.07 (−0.75, 0.89) | 0.861 |
| p ‡ | 0.001* | 0.001* | <0.001* | ||||
Data shown as mean (95% Confidence Interval). BFI, brief fatigue inventory; FACT‐F, Functional Assessment of Cancer Therapy‐Fatigue; MoCA‐K, Korean version of Montreal cognitive assessment.
*
p value less than 0.05 was considered statistically significant.
†
p value obtained from group comparisons.
‡
p value obtained from within‐group comparisons (compared to baseline value).